The effect of alogliptin against steroid-induced diabetes mellitus
Not Applicable
- Conditions
- chronic kidney disease steroid-induced diabetes mellitus
- Registration Number
- JPRN-UMIN000007032
- Lead Sponsor
- First Department of Medicine, Hamamatsu University School of Medicine
- Brief Summary
Alogliptin improves steroid induced hyperglycemia by decrease of glucagon levels through an increase in plasma GLP-1 levels.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) the patients that are suffered from diabetes mellitus The patients have thirsty, polyposia, polyuria or body weight loss that is suspicious for diabetes mellitus. Fasting glucose level>126mg/dl, postplandial blood glucose level>200mg/dl, and HbA1c>6.1% The patients have diabetic retinopathy. 2) the patients that are not suffered from severe alcholic liver damage 3) the patients that experience the administration of DPP-4 inhibitor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Fasting blood glucose level 2. Hemoglobin A1c 3. Postprandial blood glucose level in two hours after lunch
- Secondary Outcome Measures
Name Time Method 4. HOMA-R (index of insulin resistance) 5. HOMA-beta (index of insulin secretion from pancreatic beta cell) 6. DPP-4 7. incretin (Glucagon-like peptide-1) 8. glucagon